{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,24]],"date-time":"2026-09-24T09:35:43Z","timestamp":1790242543567,"version":"4.1.0"},"reference-count":103,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2015,3,1]],"date-time":"2015-03-01T00:00:00Z","timestamp":1425168000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2015,3,1]],"date-time":"2015-03-01T00:00:00Z","timestamp":1425168000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,6,8]],"date-time":"2022-06-08T00:00:00Z","timestamp":1654646400000},"content-version":"vor","delay-in-days":2656,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","exphem.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Experimental Hematology"],"published-print":{"date-parts":[[2015,3]]},"DOI":"10.1016\/j.exphem.2014.11.003","type":"journal-article","created":{"date-parts":[[2014,11,17]],"date-time":"2014-11-17T08:00:11Z","timestamp":1416211211000},"page":"158-167","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":28,"title":["Role of toll-like receptors in multiple myeloma and recent advances"],"prefix":"10.1016","volume":"43","author":[{"given":"Krishan K.","family":"Thakur","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nityanand B.","family":"Bolshette","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cristiana","family":"Trandafir","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vinayak S.","family":"Jamdade","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexandru","family":"Istrate","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ranadeep","family":"Gogoi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrei","family":"Cucuianu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.exphem.2014.11.003_bib1","doi-asserted-by":"crossref","first-page":"615","DOI":"10.1038\/sj.gene.6364337","article-title":"Gene polymorphisms in Toll-like receptors, interleukin-10, and interleukin-10 receptor alpha and lymphoma risk","volume":"7","author":"Nieters","year":"2006","journal-title":"Genes Immun"},{"key":"10.1016\/j.exphem.2014.11.003_bib2","doi-asserted-by":"crossref","first-page":"e60671","DOI":"10.1371\/journal.pone.0060671","article-title":"Characterization of the Toll-like receptor expression profile in human multiple myeloma cells","volume":"8","author":"Abdi","year":"2013","journal-title":"PLoS One"},{"key":"10.1016\/j.exphem.2014.11.003_bib3","doi-asserted-by":"crossref","first-page":"58","DOI":"10.4161\/cbt.11.1.13878","article-title":"Triggering of toll-like receptor-4 in human multiple myeloma cells promotes proliferation and alters cell responses to immune and chemotherapy drug attack","volume":"11","author":"Bao","year":"2011","journal-title":"Cancer Biol Ther"},{"key":"10.1016\/j.exphem.2014.11.003_bib4","doi-asserted-by":"crossref","first-page":"1130","DOI":"10.1038\/sj.leu.2404226","article-title":"Pathogen-associated molecular patterns are growth and survival factors for human myeloma cells through Toll-like receptors","volume":"20","author":"Jego","year":"2006","journal-title":"Leukemia"},{"key":"10.1016\/j.exphem.2014.11.003_bib5","doi-asserted-by":"crossref","first-page":"543","DOI":"10.1111\/j.1365-2141.2010.08284.x","article-title":"Expression and function of toll-like receptors in multiple myeloma patients: toll-like receptor ligands promote multiple myeloma cell growth and survival via activation of nuclear factor-kappaB","volume":"150","author":"Xu","year":"2010","journal-title":"Br J Haematol"},{"key":"10.1016\/j.exphem.2014.11.003_bib6","doi-asserted-by":"crossref","first-page":"296","DOI":"10.1182\/blood-2006-10-051482","article-title":"Plasma cells from multiple myeloma patients express B7-H1 (PD-L1) and increase expression after stimulation with IFN-{gamma} and TLR ligands via a MyD88-, TRAF6-, and MEK-dependent pathway","volume":"110","author":"Liu","year":"2007","journal-title":"Blood"},{"key":"10.1016\/j.exphem.2014.11.003_bib7","doi-asserted-by":"crossref","first-page":"e119","DOI":"10.1038\/bcj.2013.17","article-title":"Stimulation of Toll-like receptor-1\/2 combined with Velcade increases cytotoxicity to human multiple myeloma cells","volume":"3","author":"Abdi","year":"2013","journal-title":"Blood Cancer J"},{"key":"10.1016\/j.exphem.2014.11.003_bib8","doi-asserted-by":"crossref","first-page":"539","DOI":"10.1016\/S0140-6736(00)04046-0","article-title":"Inflammation and cancer: back to Virchow?","volume":"357","author":"Balkwill","year":"2001","journal-title":"Lancet"},{"key":"10.1016\/j.exphem.2014.11.003_bib9","doi-asserted-by":"crossref","first-page":"573","DOI":"10.1111\/j.1365-2567.2009.03143.x","article-title":"Plasma cell toll-like receptor (TLR) expression differs from that of B cells, and plasma cell TLR triggering enhances immunoglobulin production","volume":"128","author":"Dorner","year":"2009","journal-title":"Immunology"},{"key":"10.1016\/j.exphem.2014.11.003_bib10","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1111\/j.1399-0039.2007.00869.x","article-title":"Th2-mediated anti-tumour immunity: friend or foe?","volume":"70","author":"Ellyard","year":"2007","journal-title":"Tissue Antigens"},{"key":"10.1016\/j.exphem.2014.11.003_bib11","doi-asserted-by":"crossref","first-page":"7125","DOI":"10.4049\/jimmunol.165.12.7125","article-title":"Evidence for an accessory protein function for Toll-like receptor 1 in anti-bacterial responses","volume":"165","author":"Wyllie","year":"2000","journal-title":"J\u00a0Immunol"},{"key":"10.1016\/j.exphem.2014.11.003_bib12","doi-asserted-by":"crossref","first-page":"13213","DOI":"10.3390\/ijms140713213","article-title":"Toll-like receptor and accessory molecule mRNA expression in humans and mice as well as in murine autoimmunity, transient inflammation, and progressive fibrosis","volume":"14","author":"Ramaiah","year":"2013","journal-title":"Int J Mol Sci"},{"key":"10.1016\/j.exphem.2014.11.003_bib13","doi-asserted-by":"crossref","first-page":"4623","DOI":"10.1038\/onc.2013.432","article-title":"Immunosuppressive networks and checkpoints controlling antitumor immunity and their blockade in the development of cancer immunotherapeutics and vaccines","volume":"33","author":"Butt","year":"2014","journal-title":"Oncogene"},{"key":"10.1016\/j.exphem.2014.11.003_bib14","doi-asserted-by":"crossref","first-page":"1827","DOI":"10.2337\/dc08-0561","article-title":"Acute modulation of toll-like receptors by insulin","volume":"31","author":"Ghanim","year":"2008","journal-title":"Diabetes Care"},{"key":"10.1016\/j.exphem.2014.11.003_bib15","doi-asserted-by":"crossref","first-page":"e45011","DOI":"10.1371\/journal.pone.0045011","article-title":"Variation at innate immunity Toll-like receptor genes in a bottlenecked population of a New Zealand robin","volume":"7","author":"Grueber","year":"2012","journal-title":"PLoS One"},{"key":"10.1016\/j.exphem.2014.11.003_bib16","doi-asserted-by":"crossref","first-page":"675","DOI":"10.7150\/ijbs.6.675","article-title":"The application of Toll like receptors for cancer therapy","volume":"6","author":"So","year":"2010","journal-title":"Int J Biol Sci"},{"key":"10.1016\/j.exphem.2014.11.003_bib17","doi-asserted-by":"crossref","first-page":"6633","DOI":"10.4049\/jimmunol.166.11.6633","article-title":"A novel pathway regulating lipopolysaccharide-induced shock by ST2\/T1 via inhibition of Toll-like receptor 4 expression","volume":"166","author":"Sweet","year":"2001","journal-title":"J Immunol"},{"key":"10.1016\/j.exphem.2014.11.003_bib18","doi-asserted-by":"crossref","first-page":"208","DOI":"10.1038\/sj.onc.1210905","article-title":"Obstacles to effective Toll-like receptor agonist therapy for hematologic malignancies","volume":"27","author":"Spaner","year":"2008","journal-title":"Oncogene"},{"key":"10.1016\/j.exphem.2014.11.003_bib19","doi-asserted-by":"crossref","first-page":"4471","DOI":"10.4049\/jimmunol.0803113","article-title":"TLR3 ligand induces NF-{kappa}B activation and various fates of multiple myeloma cells depending on IFN-{alpha} production","volume":"182","author":"Chiron","year":"2009","journal-title":"J Immunol"},{"key":"10.1016\/j.exphem.2014.11.003_bib20","doi-asserted-by":"crossref","first-page":"375","DOI":"10.1016\/S1471-4906(02)02259-7","article-title":"Of mice and men: species variations of Toll-like receptor expression","volume":"23","author":"Rehli","year":"2002","journal-title":"Trends Immunol"},{"key":"10.1016\/j.exphem.2014.11.003_bib21","doi-asserted-by":"crossref","first-page":"269","DOI":"10.1016\/0092-8674(88)90516-8","article-title":"The Toll gene of Drosophila, required for dorsal-ventral embryonic polarity, appears to encode a transmembrane protein","volume":"52","author":"Hashimoto","year":"1988","journal-title":"Cell"},{"key":"10.1016\/j.exphem.2014.11.003_bib22","doi-asserted-by":"crossref","first-page":"2394","DOI":"10.4049\/jimmunol.1100515","article-title":"The role of intermediary domain of MyD88 in cell activation and therapeutic inhibition of TLRs","volume":"187","author":"Avbelj","year":"2011","journal-title":"J Immunol"},{"key":"10.1016\/j.exphem.2014.11.003_bib23","doi-asserted-by":"crossref","first-page":"397","DOI":"10.1111\/j.1365-2249.2010.04196.x","article-title":"Recent insights into the role of Toll-like receptors in viral infection","volume":"161","author":"Carty","year":"2010","journal-title":"Clin Exp Immunol"},{"key":"10.1016\/j.exphem.2014.11.003_bib24","doi-asserted-by":"crossref","first-page":"3720","DOI":"10.1182\/blood-2010-07-273417","article-title":"Interleukin-1 in the pathogenesis and treatment of inflammatory diseases","volume":"117","author":"Dinarello","year":"2011","journal-title":"Blood"},{"key":"10.1016\/j.exphem.2014.11.003_bib25","doi-asserted-by":"crossref","first-page":"637","DOI":"10.1128\/CMR.16.4.637-646.2003","article-title":"Role of Toll-like receptors in pathogen recognition","volume":"16","author":"Janssens","year":"2003","journal-title":"Clin Microbiol Rev"},{"key":"10.1016\/j.exphem.2014.11.003_bib26","doi-asserted-by":"crossref","first-page":"e84","DOI":"10.1038\/bcj.2012.29","article-title":"Epstein-Barr nuclear antigen 1 induces expression of the cellular microRNA hsa-miR-127 and impairing B-cell differentiation in EBV-infected memory B cells. New insights into the pathogenesis of Burkitt lymphoma","volume":"2","author":"Onnis","year":"2012","journal-title":"Blood Cancer J"},{"key":"10.1016\/j.exphem.2014.11.003_bib27","doi-asserted-by":"crossref","first-page":"2205","DOI":"10.1182\/blood-2008-02-140673","article-title":"Toll-like receptors: lessons to learn from normal and malignant human B cells","volume":"112","author":"Chiron","year":"2008","journal-title":"Blood"},{"key":"10.1016\/j.exphem.2014.11.003_bib28","doi-asserted-by":"crossref","first-page":"21","DOI":"10.32607\/20758251-2010-2-3-21-29","article-title":"Toll-Like Receptors (TLRs): The Role in Tumor Progression","volume":"2","author":"Shcheblyakov","year":"2010","journal-title":"Acta Naturae"},{"key":"10.1016\/j.exphem.2014.11.003_bib29","doi-asserted-by":"crossref","first-page":"e48875","DOI":"10.1371\/journal.pone.0048875","article-title":"Isolated Toll-like receptor transmembrane domains are capable of oligomerization","volume":"7","author":"Godfroy","year":"2012","journal-title":"PLoS One"},{"key":"10.1016\/j.exphem.2014.11.003_bib30","doi-asserted-by":"crossref","first-page":"e96608","DOI":"10.1371\/journal.pone.0096608","article-title":"Toll-like receptor (TLR)-1\/2 triggering of multiple myeloma cells modulates their adhesion to bone marrow stromal cells and enhances bortezomib-induced apoptosis","volume":"9","author":"Abdi","year":"2014","journal-title":"PLoS One"},{"key":"10.1016\/j.exphem.2014.11.003_bib31","doi-asserted-by":"crossref","first-page":"3154","DOI":"10.4049\/jimmunol.171.6.3154","article-title":"Subcellular localization of Toll-like receptor 3 in human dendritic cells","volume":"171","author":"Matsumoto","year":"2003","journal-title":"J Immunol"},{"key":"10.1016\/j.exphem.2014.11.003_bib32","doi-asserted-by":"crossref","first-page":"1545","DOI":"10.1016\/j.leukres.2010.06.002","article-title":"Toll-like receptors: expression and involvement in multiple myeloma","volume":"34","author":"Chiron","year":"2010","journal-title":"Leuk Res"},{"key":"10.1016\/j.exphem.2014.11.003_bib33","doi-asserted-by":"crossref","first-page":"13064","DOI":"10.1073\/pnas.1120585109","article-title":"Toll-like receptor 4 signaling in T cells promotes autoimmune inflammation","volume":"109","author":"Reynolds","year":"2012","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.exphem.2014.11.003_bib34","doi-asserted-by":"crossref","first-page":"1099","DOI":"10.1038\/35074106","article-title":"The innate immune response to bacterial flagellin is mediated by Toll-like receptor 5","volume":"410","author":"Hayashi","year":"2001","journal-title":"Nature"},{"key":"10.1016\/j.exphem.2014.11.003_bib35","doi-asserted-by":"crossref","first-page":"475","DOI":"10.4049\/jimmunol.1102977","article-title":"TLR5, a novel and unidentified inflammatory mediator in rheumatoid arthritis that correlates with disease activity score and joint TNF-alpha levels","volume":"189","author":"Chamberlain","year":"2012","journal-title":"J\u00a0Immunol"},{"key":"10.1016\/j.exphem.2014.11.003_bib36","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1016\/j.cellimm.2014.03.003","article-title":"TLR5 activation by flagellin induces doxorubicin resistance via interleukin-6 (IL-6) expression in two multiple myeloma cells","volume":"289","author":"Cho","year":"2014","journal-title":"Cell Immunol"},{"key":"10.1016\/j.exphem.2014.11.003_bib37","doi-asserted-by":"crossref","first-page":"827","DOI":"10.1038\/nn.3113","article-title":"An unconventional role for miRNA: let-7 activates Toll-like receptor 7 and causes neurodegeneration","volume":"15","author":"Lehmann","year":"2012","journal-title":"Nat Neurosci"},{"key":"10.1016\/j.exphem.2014.11.003_bib38","doi-asserted-by":"crossref","first-page":"e77159","DOI":"10.1371\/journal.pone.0077159","article-title":"Roles of TLR7 in activation of NF-kappaB signaling of keratinocytes by imiquimod","volume":"8","author":"Li","year":"2013","journal-title":"PLoS One"},{"key":"10.1016\/j.exphem.2014.11.003_bib39","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1016\/j.expneurol.2013.10.012","article-title":"Evidence for a detrimental role of TLR8 in ischemic stroke","volume":"250","author":"Tang","year":"2013","journal-title":"Exp Neurol"},{"key":"10.1016\/j.exphem.2014.11.003_bib40","doi-asserted-by":"crossref","first-page":"1949","DOI":"10.1038\/ncomms2949","article-title":"An essential role for the N-terminal fragment of Toll-like receptor 9 in DNA sensing","volume":"4","author":"Onji","year":"2013","journal-title":"Nat Commun"},{"key":"10.1016\/j.exphem.2014.11.003_bib41","doi-asserted-by":"crossref","first-page":"516","DOI":"10.1161\/ATVBAHA.113.302407","article-title":"Protective role for Toll-like receptor-9 in the development of atherosclerosis in apolipoprotein E-deficient mice","volume":"34","author":"Koulis","year":"2014","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"10.1016\/j.exphem.2014.11.003_bib42","doi-asserted-by":"crossref","first-page":"449","DOI":"10.1111\/aji.12065","article-title":"Cutting-edge report: TLR10 plays a role in mediating bacterial peptidoglycan-induced trophoblast apoptosis","volume":"69","author":"Mulla","year":"2013","journal-title":"Am J Reprod Immunol"},{"key":"10.1016\/j.exphem.2014.11.003_bib43","doi-asserted-by":"crossref","first-page":"3793","DOI":"10.1073\/pnas.1324266111","article-title":"Toll-like receptor 10 is involved in induction of innate immune responses to influenza virus infection","volume":"111","author":"Lee","year":"2014","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.exphem.2014.11.003_bib44","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1038\/nri3598","article-title":"Innate immunity to Toxoplasma gondii infection","volume":"14","author":"Yarovinsky","year":"2014","journal-title":"Nat Rev Immunol"},{"key":"10.1016\/j.exphem.2014.11.003_bib45","doi-asserted-by":"crossref","first-page":"743","DOI":"10.1038\/nature01889","article-title":"Identification of Lps2 as a key transducer of MyD88-independent TIR signalling","volume":"424","author":"Hoebe","year":"2003","journal-title":"Nature"},{"key":"10.1016\/j.exphem.2014.11.003_bib46","doi-asserted-by":"crossref","first-page":"1137","DOI":"10.1016\/j.mehy.2013.10.021","article-title":"Prophylactic broad spectrum antibiotics as a new anti-myeloma therapy","volume":"81","author":"Valkovic","year":"2013","journal-title":"Med Hypotheses"},{"key":"10.1016\/j.exphem.2014.11.003_bib47","doi-asserted-by":"crossref","first-page":"9219","DOI":"10.1200\/JCO.2005.03.2086","article-title":"Early mortality after diagnosis of multiple myeloma: analysis of patients entered onto the United kingdom Medical Research Council trials between 1980 and 2002\u2013Medical Research Council Adult Leukaemia Working Party","volume":"23","author":"Augustson","year":"2005","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.exphem.2014.11.003_bib48","doi-asserted-by":"crossref","unstructured":"Blimark C, Mellqvist UH, Landgren O, et al. Multiple myeloma and\u00a0infections: A population-based study based on 9,610 multiple myeloma patients. 2012 ASH Annual Meeting. Abstract 945. Presented December 11, 2012.","DOI":"10.1182\/blood.V120.21.945.945"},{"key":"10.1016\/j.exphem.2014.11.003_bib49","doi-asserted-by":"crossref","first-page":"812","DOI":"10.1002\/ajh.21823","article-title":"High early mortality rate in elderly patients with multiple myeloma receiving a vincristine-doxorubicin-dexamethasone regimen","volume":"85","author":"Teng","year":"2010","journal-title":"Am J Hematol"},{"key":"10.1016\/j.exphem.2014.11.003_bib50","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1016\/j.trivac.2013.09.001","article-title":"Pneumococcal vaccine responses in elderly patients with multiple myeloma, Waldenstrom\u2019s macroglobulinemia, and monoclonal gammopathy of undetermined significance","volume":"2","author":"Karlsson","year":"2013","journal-title":"Trials Vaccinol"},{"key":"10.1016\/j.exphem.2014.11.003_bib51","doi-asserted-by":"crossref","first-page":"1619","DOI":"10.1586\/erc.10.149","article-title":"Treating atherosclerosis: the potential of Toll-like receptors as therapeutic targets","volume":"8","author":"Cole","year":"2010","journal-title":"Expert Rev Cardiovasc Ther"},{"key":"10.1016\/j.exphem.2014.11.003_bib52","doi-asserted-by":"crossref","first-page":"4531","DOI":"10.4049\/jimmunol.168.9.4531","article-title":"Quantitative expression of toll-like receptor 1-10 mRNA in cellular subsets of human peripheral blood mononuclear cells and sensitivity to CpG oligodeoxynucleotides","volume":"168","author":"Hornung","year":"2002","journal-title":"J Immunol"},{"key":"10.1016\/j.exphem.2014.11.003_bib53","doi-asserted-by":"crossref","first-page":"7963","DOI":"10.4049\/jimmunol.0803864","article-title":"Cytokine modulation of TLR expression and activation in mesenchymal stromal cells leads to a proinflammatory phenotype","volume":"182","author":"Romieu-Mourez","year":"2009","journal-title":"J Immunol"},{"key":"10.1016\/j.exphem.2014.11.003_bib54","doi-asserted-by":"crossref","first-page":"157496","DOI":"10.1155\/2012\/157496","article-title":"Bone marrow microenvironment in multiple myeloma progression","volume":"2012","author":"Manier","year":"2012","journal-title":"J Biomed Biotechnol"},{"key":"10.1016\/j.exphem.2014.11.003_bib55","doi-asserted-by":"crossref","first-page":"1138","DOI":"10.1038\/sj.leu.2404225","article-title":"Toll-like receptors mediate proliferation and survival of multiple myeloma cells","volume":"20","author":"Bohnhorst","year":"2006","journal-title":"Leukemia"},{"key":"10.1016\/j.exphem.2014.11.003_bib56","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1111\/j.1600-0757.2009.00304.x","article-title":"Toll gates to periodontal host modulation and vaccine therapy","volume":"51","author":"Hajishengallis","year":"2009","journal-title":"Periodontol 2000"},{"key":"10.1016\/j.exphem.2014.11.003_bib57","doi-asserted-by":"crossref","first-page":"610","DOI":"10.1182\/blood.V95.2.610","article-title":"Expression of functional interleukin-15 receptor and autocrine production of interleukin-15 as mechanisms of tumor propagation in multiple myeloma","volume":"95","author":"Tinhofer","year":"2000","journal-title":"Blood"},{"key":"10.1016\/j.exphem.2014.11.003_bib58","doi-asserted-by":"crossref","first-page":"14","DOI":"10.4110\/in.2014.14.1.14","article-title":"NF-kappaB Activation in T Helper 17 Cell Differentiation","volume":"14","author":"Park","year":"2014","journal-title":"Immune Netw"},{"key":"10.1016\/j.exphem.2014.11.003_bib59","doi-asserted-by":"crossref","first-page":"190","DOI":"10.1046\/j.1365-2249.2001.01582.x","article-title":"Deregulated cytokine network and defective Th1 immune response in multiple myeloma","volume":"125","author":"Frassanito","year":"2001","journal-title":"Clin Exp Immunol"},{"key":"10.1016\/j.exphem.2014.11.003_bib60","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1038\/sj.leu.2404456","article-title":"Toll-like receptor agonists in the treatment of chronic lymphocytic leukemia","volume":"21","author":"Spaner","year":"2007","journal-title":"Leukemia"},{"key":"10.1016\/j.exphem.2014.11.003_bib61","doi-asserted-by":"crossref","first-page":"640","DOI":"10.1126\/science.1087262","article-title":"Role of adaptor TRIF in the MyD88-independent toll-like receptor signaling pathway","volume":"301","author":"Yamamoto","year":"2003","journal-title":"Science"},{"key":"10.1016\/j.exphem.2014.11.003_bib62","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1016\/j.critrevonc.2010.12.001","article-title":"The role of toll-like receptor mediated signalling in the pathogenesis of multiple myeloma","volume":"80","author":"Abdi","year":"2011","journal-title":"Crit Rev Oncol Hematol"},{"key":"10.1016\/j.exphem.2014.11.003_bib63","doi-asserted-by":"crossref","first-page":"753407","DOI":"10.1155\/2012\/753407","article-title":"Novel strategies for immunotherapy in multiple myeloma: previous experience and future directions","volume":"2012","author":"Danylesko","year":"2012","journal-title":"Clin Dev Immunol"},{"key":"10.1016\/j.exphem.2014.11.003_bib64","doi-asserted-by":"crossref","first-page":"3131","DOI":"10.4049\/jimmunol.0903605","article-title":"CpG-oligodeoxynucleotide inhibits Smad-dependent bone morphogenetic protein signaling: effects on myeloma cell apoptosis and in\u00a0vitro osteoblastogenesis","volume":"185","author":"Norgaard","year":"2010","journal-title":"J\u00a0Immunol"},{"key":"10.1016\/j.exphem.2014.11.003_bib65","doi-asserted-by":"crossref","first-page":"460","DOI":"10.1016\/j.molmed.2007.09.002","article-title":"Signaling to NF-kappaB by Toll-like receptors","volume":"13","author":"Kawai","year":"2007","journal-title":"Trends Mol Med"},{"key":"10.1016\/j.exphem.2014.11.003_bib66","doi-asserted-by":"crossref","first-page":"3311","DOI":"10.1002\/eji.200737744","article-title":"Toll-like receptors' two-edged sword: when immunity meets apoptosis","volume":"37","author":"Salaun","year":"2007","journal-title":"Eur J Immunol"},{"key":"10.1016\/j.exphem.2014.11.003_bib67","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1016\/j.coi.2008.04.010","article-title":"Activation-dependent induction of Blimp-1","volume":"20","author":"Calame","year":"2008","journal-title":"Curr Opin Immunol"},{"key":"10.1016\/j.exphem.2014.11.003_bib68","doi-asserted-by":"crossref","first-page":"1471","DOI":"10.1084\/jem.20051611","article-title":"Blimp-1 is required for maintenance of long-lived plasma cells in the bone marrow","volume":"202","author":"Shapiro-Shelef","year":"2005","journal-title":"J Exp Med"},{"key":"10.1016\/j.exphem.2014.11.003_bib69","doi-asserted-by":"crossref","first-page":"3305","DOI":"10.1182\/blood-2014-02-554071","article-title":"TPL2 kinase regulates the inflammatory milieu of the myeloma niche","volume":"123","author":"Hope","year":"2014","journal-title":"Blood"},{"key":"10.1016\/j.exphem.2014.11.003_bib70","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.canlet.2008.08.005","article-title":"Cancer stem cells in multiple myeloma","volume":"277","author":"Ghosh","year":"2009","journal-title":"Cancer Lett"},{"key":"10.1016\/j.exphem.2014.11.003_bib71","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1002\/ajh.23387","article-title":"Identification of an ABCB1 (P-glycoprotein)-positive carfilzomib-resistant myeloma subpopulation by the pluripotent stem cell fluorescent dye CDy1","volume":"88","author":"Hawley","year":"2013","journal-title":"Am J Hematol"},{"key":"10.1016\/j.exphem.2014.11.003_bib72","doi-asserted-by":"crossref","first-page":"e219","DOI":"10.1038\/bcj.2014.38","article-title":"The novel immunotoxin HM1.24-ETA' induces apoptosis in multiple myeloma cells","volume":"4","author":"Staudinger","year":"2014","journal-title":"Blood Cancer J"},{"key":"10.1016\/j.exphem.2014.11.003_bib73","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1128\/IAI.00856-07","article-title":"Mechanisms of dexamethasone-mediated inhibition of Toll-like receptor signaling induced by Neisseria meningitidis and Streptococcus pneumoniae","volume":"76","author":"Mogensen","year":"2008","journal-title":"Infect Immun"},{"key":"10.1016\/j.exphem.2014.11.003_bib74","doi-asserted-by":"crossref","first-page":"1332","DOI":"10.1038\/nm.2938","article-title":"The tumor microenvironment controls drug sensitivity","volume":"18","author":"Ostman","year":"2012","journal-title":"Nat Med"},{"key":"10.1016\/j.exphem.2014.11.003_bib75","doi-asserted-by":"crossref","first-page":"1264","DOI":"10.1158\/1078-0432.CCR-10-1805","article-title":"Treatment options for relapsed and refractory multiple myeloma","volume":"17","author":"Lonial","year":"2011","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.exphem.2014.11.003_bib76","doi-asserted-by":"crossref","first-page":"1716","DOI":"10.1038\/leu.2014.46","article-title":"A novel TLR-9 agonist C792 inhibits plasmacytoid dendritic cell-induced myeloma cell growth and enhance cytotoxicity of bortezomib","volume":"28","author":"Ray","year":"2014","journal-title":"Leukemia"},{"key":"10.1016\/j.exphem.2014.11.003_bib77","doi-asserted-by":"crossref","first-page":"441","DOI":"10.1111\/ejh.12107","article-title":"Monoclonal antibodies: potential new therapeutic treatment against multiple myeloma","volume":"90","author":"Allegra","year":"2013","journal-title":"Eur J Haematol"},{"key":"10.1016\/j.exphem.2014.11.003_bib78","doi-asserted-by":"crossref","first-page":"218","DOI":"10.1038\/sj.onc.1210904","article-title":"TLR signaling by tumor and immune cells: a double-edged sword","volume":"27","author":"Huang","year":"2008","journal-title":"Oncogene"},{"key":"10.1016\/j.exphem.2014.11.003_bib79","doi-asserted-by":"crossref","first-page":"167","DOI":"10.4331\/wjbc.v2.i7.167","article-title":"Toll-like receptors are potential therapeutic targets in rheumatoid arthritis","volume":"2","author":"Shotorbani","year":"2011","journal-title":"World J Biol Chem"},{"key":"10.1016\/j.exphem.2014.11.003_bib80","doi-asserted-by":"crossref","first-page":"156","DOI":"10.1138\/20100440","article-title":"RANKing bone resorption versus inflammation: Infection makes the decision","volume":"7","author":"Ferrari-Lacraz","year":"2010","journal-title":"IBMS BoneKEy"},{"key":"10.1016\/j.exphem.2014.11.003_bib81","doi-asserted-by":"crossref","first-page":"364","DOI":"10.1093\/cvr\/cvt033","article-title":"Toll-like receptor 3 and 4 signalling through the TRIF and TRAM adaptors in haematopoietic cells promotes atherosclerosis","volume":"99","author":"Lundberg","year":"2013","journal-title":"Cardiovasc Res"},{"key":"10.1016\/j.exphem.2014.11.003_bib82","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1124\/pr.109.001073","article-title":"Therapeutic targeting of Toll-like receptors for infectious and inflammatory diseases and cancer","volume":"61","author":"O'Neill","year":"2009","journal-title":"Pharmacol Rev"},{"key":"10.1016\/j.exphem.2014.11.003_bib83","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1080\/08923970902802926","article-title":"The potential use of Toll-like receptor (TLR) agonists and antagonists as prophylactic and\/or therapeutic agents","volume":"31","author":"Makkouk","year":"2009","journal-title":"Immunopharmacol Immunotoxicol"},{"key":"10.1016\/j.exphem.2014.11.003_bib84","doi-asserted-by":"crossref","first-page":"953","DOI":"10.1002\/ajh.23280","article-title":"Prolonged subcutaneous administration of 852A, a novel systemic toll-like receptor 7 agonist, to activate innate immune responses in patients with advanced hematologic malignancies","volume":"87","author":"Weigel","year":"2012","journal-title":"Am J Hematol"},{"key":"10.1016\/j.exphem.2014.11.003_bib85","doi-asserted-by":"crossref","first-page":"1304","DOI":"10.1182\/blood-2012-07-442590","article-title":"TLR9-mediated siRNA delivery for targeting of normal and malignant human hematopoietic cells in\u00a0vivo","volume":"121","author":"Zhang","year":"2013","journal-title":"Blood"},{"key":"10.1016\/j.exphem.2014.11.003_bib86","doi-asserted-by":"crossref","first-page":"1110","DOI":"10.1038\/emboj.2008.31","article-title":"Toll-like receptors control autophagy","volume":"27","author":"Delgado","year":"2008","journal-title":"EMBO J"},{"key":"10.1016\/j.exphem.2014.11.003_bib87","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1093\/intimm\/dxh186","article-title":"Toll-like receptors in innate immunity","volume":"17","author":"Takeda","year":"2005","journal-title":"Int Immunol"},{"key":"10.1016\/j.exphem.2014.11.003_bib88","doi-asserted-by":"crossref","first-page":"607","DOI":"10.1182\/blood-2004-01-0037","article-title":"Advances in biology of multiple myeloma: clinical applications","volume":"104","author":"Hideshima","year":"2004","journal-title":"Blood"},{"key":"10.1016\/j.exphem.2014.11.003_bib89","doi-asserted-by":"crossref","first-page":"1285","DOI":"10.1172\/JCI36551","article-title":"Triggering of TLR7 and TLR8 expressed by human lung cancer cells induces cell survival and chemoresistance","volume":"120","author":"Cherfils-Vicini","year":"2010","journal-title":"J Clin Invest"},{"key":"10.1016\/j.exphem.2014.11.003_bib90","doi-asserted-by":"crossref","first-page":"3642","DOI":"10.1158\/1535-7163.MCT-08-0582","article-title":"Activation of Toll-like receptors 2, 3, and 4 on human melanoma cells induces inflammatory factors","volume":"7","author":"Goto","year":"2008","journal-title":"Mol Cancer Ther"},{"key":"10.1016\/j.exphem.2014.11.003_bib91","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1186\/1476-4598-12-77","article-title":"The regulation of Toll-like receptor 2 by miR-143 suppresses the invasion and migration of a subset of human colorectal carcinoma cells","volume":"12","author":"Guo","year":"2013","journal-title":"Mol Cancer"},{"key":"10.1016\/j.exphem.2014.11.003_bib92","doi-asserted-by":"crossref","first-page":"248","DOI":"10.2478\/s11658-008-0048-z","article-title":"Toll-like receptors and their role in carcinogenesis and anti-tumor treatment","volume":"14","author":"Wolska","year":"2009","journal-title":"Cell Mol Biol Lett"},{"key":"10.1016\/j.exphem.2014.11.003_bib93","doi-asserted-by":"crossref","first-page":"6520","DOI":"10.1038\/sj.onc.1209653","article-title":"Interference with nuclear factor kappa B and c-Jun NH2-terminal kinase signaling by TRAF6C small interfering RNA inhibits myeloma cell proliferation and enhances apoptosis","volume":"25","author":"Chen","year":"2006","journal-title":"Oncogene"},{"key":"10.1016\/j.exphem.2014.11.003_bib94","doi-asserted-by":"crossref","first-page":"3341","DOI":"10.1016\/j.vaccine.2010.08.002","article-title":"TLR-based immune adjuvants","volume":"29","author":"Steinhagen","year":"2011","journal-title":"Vaccine"},{"key":"10.1016\/j.exphem.2014.11.003_bib95","first-page":"21","article-title":"The future of toll-like receptor therapeutics","volume":"10","author":"Parkinson","year":"2008","journal-title":"Curr Opin Mol Ther"},{"key":"10.1016\/j.exphem.2014.11.003_bib96","doi-asserted-by":"crossref","first-page":"e25238","DOI":"10.4161\/onci.25238","article-title":"Toll-like receptor agonists for cancer therapy","volume":"2","author":"Vacchelli","year":"2013","journal-title":"OncoImmunology"},{"key":"10.1016\/j.exphem.2014.11.003_bib97","doi-asserted-by":"crossref","first-page":"13503","DOI":"10.3390\/molecules171113503","article-title":"Therapeutic applications of nucleic acids and their analogues in toll-like receptor signaling","volume":"17","author":"Gosu","year":"2012","journal-title":"Molecules"},{"key":"10.1016\/j.exphem.2014.11.003_bib98","doi-asserted-by":"crossref","first-page":"1314","DOI":"10.1093\/annonc\/mdr363","article-title":"An intra-patient placebo-controlled phase I trial to evaluate the safety and tolerability of intradermal IMM-101 in melanoma","volume":"23","author":"Stebbing","year":"2012","journal-title":"Ann Oncol"},{"key":"10.1016\/j.exphem.2014.11.003_bib99","doi-asserted-by":"crossref","first-page":"6186","DOI":"10.4049\/jimmunol.0901474","article-title":"AS04, an aluminum salt- and TLR4 agonist-based adjuvant system, induces a transient localized innate immune response leading to enhanced adaptive immunity","volume":"183","author":"Didierlaurent","year":"2009","journal-title":"J Immunol"},{"key":"10.1016\/j.exphem.2014.11.003_bib100","doi-asserted-by":"crossref","first-page":"214","DOI":"10.3389\/fimmu.2013.00214","article-title":"Vaccine adjuvants: mode of action","volume":"4","author":"De Gregorio","year":"2013","journal-title":"Front Immunol"},{"key":"10.1016\/j.exphem.2014.11.003_bib101","doi-asserted-by":"crossref","first-page":"e84634","DOI":"10.1371\/journal.pone.0084634","article-title":"Suppression of molecular inflammatory pathways by Toll-like receptor 7, 8, and 9 antagonists in a model of IL-23-induced skin inflammation","volume":"8","author":"Su\u00e1rez-Fari\u00f1as","year":"2013","journal-title":"PLoS One"},{"key":"10.1016\/j.exphem.2014.11.003_bib102","doi-asserted-by":"crossref","first-page":"787","DOI":"10.1007\/s00262-014-1547-6","article-title":"Antitumor activity and safety of combination therapy with the Toll-like receptor 9 agonist IMO-2055, erlotinib, and bevacizumab in advanced or metastatic non-small cell lung cancer patients who have progressed following chemotherapy","volume":"63","author":"Smith","year":"2014","journal-title":"Cancer Immunol Immunother"},{"key":"10.1016\/j.exphem.2014.11.003_bib103","doi-asserted-by":"crossref","first-page":"557","DOI":"10.4161\/cbt.24598","article-title":"Phase 2 trial of erlotinib with or without PF-3512676 (CPG 7909, a Toll-like receptor 9 agonist) in patients with advanced recurrent EGFR-positive non-small cell lung cancer","volume":"14","author":"Belani","year":"2013","journal-title":"Cancer Biol Ther"}],"container-title":["Experimental Hematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0301472X1400753X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0301472X1400753X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,4]],"date-time":"2025-10-04T08:32:34Z","timestamp":1759566754000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0301472X1400753X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,3]]},"references-count":103,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2015,3]]}},"alternative-id":["S0301472X1400753X"],"URL":"https:\/\/doi.org\/10.1016\/j.exphem.2014.11.003","relation":{},"ISSN":["0301-472X"],"issn-type":[{"value":"0301-472X","type":"print"}],"subject":[],"published":{"date-parts":[[2015,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Role of toll-like receptors in multiple myeloma and recent advances","name":"articletitle","label":"Article Title"},{"value":"Experimental Hematology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.exphem.2014.11.003","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2015 ISEH - International Society for Experimental Hematology. Published by Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}